With this approval, about 300 children between 12 months and 24 months will be eligible for treatment with Orkambi.
The FDA has approved expanded the use of Vertex Pharmaceuticals’ Orkambi (lumacaftor/ivacaftor) to include children with cystic fibrosis (CF) ages 12 months to <24 months with two copies of the F508del mutation. Orkambi was previously approved for use in patients ages 2 years and older with two copies of the F508del mutation.
Cystic fibrosis is a rare, life-shortening genetic disease that affects more than 83,000 people globally. It is a progress disease that can affects the lungs, liver, pancreas, GI tract, sinuses, sweat glands and reproductive tract. Cystic fibrosis is caused by a defective and/or missing CFTR protein resulting from certain mutations in the CFTR gene, and children must inherit two defective genes to have cystic fibrosis.
“Treating children with cystic fibrosis as early in life as possible is critically important, because early treatment has the potential to slow the progression of this devastating disease,” Carmen Bozic, M.D., executive vice president, global medicines development and medical affairs, and chief medical officer of Vertex, said in a press release.
The approval in children ages 12 months to <24 months is based on a 24-week, phase 3 study in 46 children ages 1 to less than 2 years with the two copies of the F508del mutation. Orkambiwas generally well tolerated, and the safety profile and pharmacokinetics were similar to that observed in studies in patients ages 2 years and older. Additional study results, including reductions in sweat chloride concentration, suggest the potential for CF disease modification with the use of Orkambi.
Orkambi as first approved in 2015 in the United States and is now available in more than 30 countries. The average wholesale price of Orkambi is $26,333.12 for 112 tablets, or $235.11 per tablet, according to Vertex. It is also available as oral granules for reconstitution.
FDA Issues Complete Response Letter for Pz-Cel to Treat Epidermolysis Bullosa
April 22nd 2024Prademagene zamikeracel is a cell therapy designed to incorporate the functional collagen-producing COL7A1 gene into a patient’s own skin cells. The FDA is asking for additional information on manufacturing practices.
Read More
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
FDA Approves Stelara Biosimilar, Selarsdi
April 18th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Read More